 |
 |
 |
|
TELAPREVIR IN THE TREATMENT OF ACUTE HCV INFECTION IN HIV-INFECTED MEN
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Daniel S. Fierer1, Douglas Dieterich2, Michael Mullen1, Andrea D. Branch2, Alison J. Uriel2, 3, Damaris C. Carriero2, 4, Wouter O. van Seggelen1, 5, Rosanne M. Hijdra1, 5 , David Cassagnol1, 6, Tristan Morey1, 7
Divisions of 1Infectious Diseases and 2Liver Diseases, Icahn School of Medicine at Mount Sinai; 4Columbia University School of Medicine, and 6Weill Cornell Medical College, New York, USA; 3N. Manchester General Hospital,
Manchester, UK; 5Amsterdam Medical Center, Amsterdam, The Netherlands; and 7James Cook University, Cairns, QLD, Australia



|
|
|
 |
 |
|
|